Multiparameter immunoprofiling for the diagnosis and differentiation of progressive versus nonprogressive nontuberculous mycobacterial lung disease-A pilot study

Clinical prediction of nontuberculous mycobacteria lung disease (NTM-LD) progression remains challenging. We aimed to evaluate antigen-specific immunoprofiling utilizing flow cytometry (FC) of activation-induced markers (AIM) and IFN-γ enzyme-linked immune absorbent spot assay (ELISpot) accurately i...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2024-04, Vol.19 (4), p.e0301659-e0301659
Main Authors: Marty, Paige K, Pathakumari, Balaji, Cox, Thomas M, Van Keulen, Virginia P, Erskine, Courtney L, Shah, Maleeha, Vadiyala, Mounika, Arias-Sanchez, Pedro, Karnakoti, Snigdha, Pennington, Kelly M, Theel, Elitza S, Lindestam Arlehamn, Cecilia S, Peikert, Tobias, Escalante, Patricio
Format: Article
Language:English
Subjects:
Antigens
Care and treatment
Control
Diagnosis
Humans
Identification and classification
Leukocytes, Mononuclear
Lung diseases
Mycobacteria
Mycobacterium
Mycobacterium Infections, Nontuberculous - microbiology
Nontuberculous Mycobacteria
Pilot Projects
Pneumonia
Prospective Studies
Risk factors
Testing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical prediction of nontuberculous mycobacteria lung disease (NTM-LD) progression remains challenging. We aimed to evaluate antigen-specific immunoprofiling utilizing flow cytometry (FC) of activation-induced markers (AIM) and IFN-γ enzyme-linked immune absorbent spot assay (ELISpot) accurately identifies patients with NTM-LD, and differentiate those with progressive from nonprogressive NTM-LD. A Prospective, single-center, and laboratory technician-blinded pilot study was conducted to evaluate the FC and ELISpot based immunoprofiling in patients with NTM-LD (n = 18) and controls (n = 22). Among 18 NTM-LD patients, 10 NTM-LD patients were classified into nonprogressive, and 8 as progressive NTM-LD based on clinical and radiological features. Peripheral blood mononuclear cells were collected from patients with NTM-LD and control subjects with negative QuantiFERON results. After stimulation with purified protein derivative (PPD), mycobacteria-specific peptide pools (MTB300, RD1-peptides), and control antigens, we performed IFN-γ ELISpot and FC AIM assays to access their diagnostic accuracies by receiver operating curve (ROC) analysis across study groups. Patients with NTM-LD had significantly higher percentage of CD4+/CD8+ T-cells co-expressing CD25+CD134+ in response to PPD stimulation, differentiating between NTM-LD and controls. Among patients with NTM-LD, there was a significant difference in CD25+CD134+ co-expression in MTB300-stimulated CD8+ T-cells (p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0301659